Key result
Novel oral anticoagulants are at least as effective as warfarin for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation, with significantly lower rates of intracranial hemorrhage.
Why the study?
Does novel oral anticoagulants prevent stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation?
Does novel oral anticoagulants prevent stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation?
NOACs offer an effective and generally safer alternative to warfarin for stroke prevention in non-valvular atrial fibrillation, particularly by reducing the risk of intracranial hemorrhage.
Supports preferential NOAC use over warfarin in non-valvular AF; confirms Level 1 evidence in guidelines.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Ischemic stroke and systemic thromboembolism are the most fatal complications of AF. Vitamin K antagonists (VKA) are used in the prevention of AF-related stroke and systemic thromboembolism. However, the use of VKAs is associated with limitations such as their narrow therapeutic index, the need for monitoring, and numerous food-drug interactions. Novel oral anticoagulants (NOACs) developed by researchers do not have those limitations and are better tolerated in patients with non-valvular atrial fibrillation. In this review, the pharmacological properties of NOACs, the results of NOAC clinical trials, the guideline recommendations, the important aspects of patient selection and clinical practice, new antidote drugs for NOACs and real-world data of NOACs in patients with non-valvular atrial fibrillation have been discussed.
No takes yet. Share an insight, caveat, or question.
Kocabaş et al. (2016) conducted a review in Non-valvular atrial fibrillation. Novel oral anticoagulants (NOACs) vs. Vitamin K antagonists (warfarin) was evaluated. Novel oral anticoagulants are at least as effective as warfarin for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation, with significantly lower rates of intracranial hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: